For personal injury attorneys. Neurologists and other physicians who evaluate patients after injury are welcome as guests. The accredited instructional program runs from 12:15 to 1:15 p.m.; check-in and lunch begin at noon, and networking continues until 1:30 p.m.
About the program
Blood biomarker findings increasingly appear in the discussion of traumatic brain injury, but a laboratory value must be interpreted in context. This 60-minute legal education program examines the scientific foundation and limits of these markers, the clinical questions they may inform, and their responsible use in personal injury litigation. The faculty will distinguish an observed laboratory result from a clinical diagnosis and from an opinion about causation.
Learning objectives
After the program, attorney attendees should be able to:
- Identify the evidence and assay information needed to evaluate the reliability and relevance of a blood biomarker result.
- Explain how collection timing, reference information, age, other neurologic conditions, and extracranial injury can affect interpretation.
- Frame appropriate discovery, expert, and admissibility questions without treating a single value as proof of TBI or injury causation.
- Recognize differences between acute, subacute, and later testing, including areas where the evidence remains limited.
Program and faculty
| Time | Topic | Faculty role |
|---|---|---|
| 12:00–12:15 p.m. | Check-in and lunch | No instructional credit claimed |
| 12:15–12:35 p.m. | Scientific evidence and admissibility | Gary Marchant, J.D., Ph.D., lead CLE faculty |
| 12:35–12:45 p.m. | Biomarker methods and limitations | Javid A. Wani, Ph.D., laboratory science |
| 12:45–12:55 p.m. | Clinical context and alternative causes | Cabe Owens, M.D., Ph.D., clinical interpretation |
| 12:55–1:10 p.m. | Responsible use in TBI litigation | Premkiran Reddy, M.D., J.D., F.C.L.M., moderator and trial practice |
| 1:10–1:15 p.m. | Faculty questions | All faculty |
| 1:15–1:30 p.m. | Networking | No instructional credit claimed |
Gary E. Marchant, J.D., Ph.D. is Regents and Foundation Professor of Law and Faculty Director of the Center for Law, Science and Innovation at Arizona State University's Sandra Day O'Connor College of Law. His work addresses the legal governance of emerging science and technology, including genomics, personalized medicine, and neuroscience. He co-authored Biomarkers, Concussions, and the Duty of Care with Betsy Grey. ASU faculty profile
Javid A. Wani, Ph.D. is President and CEO of TBioScan Inc. He will explain the analytical questions a lawyer should ask about biomarker methods, validation, reference information, and report limitations.
Cabe Owens, M.D., Ph.D. is a TBI neurologist at Elevated Med Solutions. He will discuss how a clinician places laboratory findings alongside the history, examination, imaging, and alternative explanations.
Premkiran Reddy, M.D., J.D., F.C.L.M. is a TBI trial attorney at Reddy's Law Firm. He will moderate the discussion and address practical uses and limits of biomarker evidence in litigation.
Featured reading
- Grey, Betsy and Marchant, Gary E., Biomarkers, Concussions, and the Duty of Care (October 13, 2015), 2015 Michigan State Law Review 1911. The article provides legal context for biomarker evidence; it is not a validation study of the TBioScan test menu.
- For current clinical context: Bazarian JJ, et al., Blood-Based Biomarkers for Improved Characterization of Traumatic Brain Injury, Journal of Neurotrauma 2025;42:1065-1085. PubMed PMID 40393505.
Credit and attendance
This course has been approved for Minimum Continuing Legal Education credit by the State Bar of Texas Committee on MCLE in the amount of 1.0 credit hours, of which 0.0 credit hours will apply to legal ethics/professional responsibility credit.
Attorneys seeking credit should check in and attend the full 12:15–1:15 p.m. instructional program. The sponsor will maintain attendance records and report attendance as required. No CME credit is offered.
About the organizers
TBioScan Inc. is a Delaware corporation with a place of business at River Oaks Medical Center, 4120 Southwest Fwy, Ste 175, Houston, TX 77027. TBioScan Blood Biomarker Testing is powered by BioCentra Diagnostics, a CAP-accredited and CLIA-certified high-complexity laboratory in Houston. The event is co-sponsored by Elevated Med Solutions, Houston.
The educational program addresses the scientific and legal issues independently of any product selection or ordering decision.
Frequently asked questions
- Can physicians attend?
- Yes. Neurologists and other physicians involved in injury evaluation are welcome. The course is designed for attorneys, and CME credit is not offered.
- Does a positive marker establish TBI or causation?
- No. A clinician must interpret results with the injury history, collection timing, examination, imaging, assay-specific reference information, and other possible causes.
- Does the program address later testing?
- Yes. Faculty will discuss the distinction between established acute and subacute evidence and the more limited evidence for routine use beyond 30 days.
- Is the TBioScan panel FDA-cleared?
- TBioScan testing is laboratory-developed and is not FDA-cleared. Clearance of a different acute TBI assay does not extend to this test menu.